摘要
目的分析法舒地尔联合沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病(COPD)合并肺动脉高压的临床效果。方法抽取2018年7月至2021年6月开封市人民医院收治的90例COPD合并肺动脉高压患者作为研究对象, 按随机数字表法分为单一组和联合组, 每组45例。单一组采用法舒地尔治疗, 联合组采用法舒地尔联合沙美特罗替卡松粉吸入剂治疗。比较两组临床疗效、肺功能、血气指标水平及不良反应发生情况。结果联合组总有效率为95.56%(43/45)高于单一组的82.22%(37/45), (P<0.05);治疗后, 联合组FEV1、FEV1/FVC水平高于单一组(P<0.05);治疗后, 联合组氧分压、血氧饱和度高于单一组(P<0.05);联合组不良反应发生率11.11%(5/45)与单一组8.89%(4/45)比较差异未见统计学意义(P>0.05)。结论法舒地尔联合沙美特罗替卡松粉吸入剂治疗COPD合并肺动脉高压, 可提高临床疗效, 改善患者血气指标和肺功能, 安全性高。
Objective To analyze the clinical effect of fasudil combined with salmeterol xinafoate and fluticasone propionate powder for inhalation in the treatment of chronic obstructive pulmonary disease(COPD)complicated by pulmonary hypertension.Methods A total of 90 patients with COPD complicated by pulmonary hypertension treated in Kaifeng People’s Hospital from July 2018 to June 2021 were selected and divided into single group and combined group according to random number table method,with 45 cases in each group.The single group was treated with fasudil,and the combined group was treated with fasudil combined with salmeterol xinafoate and fluticasone propionate powder for inhalation.The efficacy,lung function,blood gas index levels,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the combined group was 95.56%(43/45),which was higher than the 82.22%(37/45)of the single group(P<0.05).After treatment,the levels of forced expiratory volume in one second and ratio of forced expiratory volume in one second to forced vital capacity in the combined group were higher than those in the single group(P<0.05).After treatment,the oxygen partial pressure and blood oxygen saturation of the combined group were higher than those of the single group(P<0.05).There was no significant difference in the incidence of adverse reactions between the combined group(11.11%,5/45)and the single group(8.89%,4/45),P>0.05.Conclusions Fasudil combined with salmeterol xinafoate and fluticasone propionate powder for inhalation in the treatment of COPD complicated by pulmonary hypertension can improve the clinical efficacy,blood gas index and pulmonary function,with high safety.
作者
王红丽
杨亚敏
霍凤玲
Wang Hongli;Yang Yamin;Huo Fengling(Department of Respiratory Medicine,Kaifeng People’s Hospital,Kaifeng 475000,China)
出处
《中国实用医刊》
2022年第11期95-98,共4页
Chinese Journal of Practical Medicine
关键词
慢性阻塞性肺疾病
肺动脉高压
法舒地尔
沙美特罗替卡松
Chronic obstructive pulmonary disease
Pulmonary hypertension
Fasudil
Salmeterol and fluticasone propionate